Evidence map›Paper›PMID 36530588›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2022

Elevated Serum Osteoprotegerin is Associated with Reduced Risks of Albuminuria and CKD Progression in Patients with Type 2 Diabetes.

Xiaoyang Lou, Zhi Yang, Kexia Wu, Weihong Li, Wan Hu, Ronghui Nie, Ping Tu, Peng Duan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoyang Lou *Department of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Zhi Yang *Department of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Kexia Wu *Department of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Weihong LiDepartment of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Wan HuDepartment of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Ronghui NieDepartment of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Ping TuDepartment of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.
Peng DuanDepartment of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, Jiangxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To analyze the correlation between serum osteoprotegerin (OPG) level and chronic kidney disease (CKD) at different CKD stages in patients with type 2 diabetes. Methods: All subjects were hospitalized patients with type 2 diabetes. Medical history collection, physical examinations, and blood and urine samples testing were performed. Stages of CKD (G1-5) were defined by eGFR, groups of persistent albuminuria (normal, microalbuminuria and massive albuminuria) were divided by UACR, and categories of CKD progression risks (low, moderate and high or very high risk) were recommended by the Kidney Disease: Improving Global Outcomes (KDIGO). Serum OPG level was determined by enzyme-linked immunosorbent assay in the central laboratory. Results: Four hundred and eighty-four patients were included in the study. The average level of OPG of all subjects was 941.30 (547.53-1332.62) pg/mL. The levels of OPG decreased gradually with the aggravation of albuminuria (P = 0.007, P Conclusion: In patients with type 2 diabetes, elevated serum osteoprotegerin is associated with albuminuria and the risk of CKD progression, and may delay the progression of CKD.

Indexed as

albuminuriachronic kidney diseaseglomerular filtration rateosteoprotegerintype 2 diabetes mellitus

Identifiers

PMID36530588
PMCPMC9756793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.